Efficacy and safety of dapnetin capsules in the treatment of patients with simple varicose veins of the lower extremities combined with superficial thrombophlebitis - a prospective, multicenter, randomized controlled study

Efficacy and safety of dapnetin capsules in the treatment of patients with simple varicose veins of the lower extremities combined with superficial thrombophlebitis - a prospective, multicenter, randomized controlled study - Efficacy and safety of dapnetin capsules in the treatment of simple varicose veins of lower extremities complicated with superficial thrombotic phlebitis

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2500095975

Enrollment

Unknown

Registered

2025-01-15

Start date

2025-02-01

Completion date

Unknown

Last updated

2025-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Simple varicose veins of lower extremity with superficial thrombophlebitis

Interventions

control group:conventional medical treatment as described in the guidelines.

experimental group:conventional medical treatment with oral dapnetin capsules. 0.15g/ pill, 0.45g/ time, 3 times/day for 12 weeks.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-75 years old (including 18 and 75 years old), gender is not limited; 2. Diagnostic criteria for superficial thrombophlebitis refer to "Practical Internal Medicine" : redness, tenderness, strip-like hard matter in the superficial vein area; 3. The diagnostic criteria for simple varicose veins of the lower extremities refer to the Chinese Guidelines for the Diagnosis and Treatment of Chronic Venous Diseases, and the clinical grade of CEAP is C2-4. 4.No surgical treatment or sclerosing agent is prepared during the 12-week treatment period; Informed consent and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with coagulation dysfunction have a tendency to hemorrhage after surgery; 2. Patients with unmanageable diabetes, severe hypertension or any other clinically significant abnormality; 3. People who are allergic to dapnetin; 4. Patients with deep venous thrombosis of lower extremity; 5. Serious heart, kidney, liver disease, liver and kidney insufficiency; 6. Pregnant or lactating women; The investigator believes that there are any circumstances that may affect the subject's ability to provide informed consent or to follow the trial protocol, or that the subject's participation in the trial may affect the trial results or his or her own safety, or that the investigator believes there are other circumstances that make participation in the clinical trial inappropriate.

Design outcomes

Primary

Measure	Time frame
venousclinical severity score;	—

Secondary

Measure	Time frame
CEAP clinical classification;chronic venous insufficiency questionnaire;Blood clotting four;Vascular Doppler ultrasound;	—

Countries

China

Contacts

Public ContactYin Qiang

The Second Affiliated Hospital of Xi 'an Medical University

110569176@qq.com+86 135 7200 1886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026